Oruka Therapeutics, Inc. - 8-K Filing
Oruka Therapeutics reports positive Week 16 Phase 2b EVERLAST-B trial results for ORKA-001 in moderate-to-severe plaque psoriasis. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $ORKA
Read the full article at SEC EDGAR
Part of the story Climb Bio, Inc. - 8-K Filing (3 articles)